[go: up one dir, main page]

BRPI0814624A2 - Tratamento de doença neurodegenerativa progresiva com ibudilaste - Google Patents

Tratamento de doença neurodegenerativa progresiva com ibudilaste

Info

Publication number
BRPI0814624A2
BRPI0814624A2 BRPI0814624-1A2A BRPI0814624A BRPI0814624A2 BR PI0814624 A2 BRPI0814624 A2 BR PI0814624A2 BR PI0814624 A BRPI0814624 A BR PI0814624A BR PI0814624 A2 BRPI0814624 A2 BR PI0814624A2
Authority
BR
Brazil
Prior art keywords
progresive
ibudilast
treatment
neurodegenerative disease
neurodegenerative
Prior art date
Application number
BRPI0814624-1A2A
Other languages
English (en)
Inventor
Michael E Kalafer
Kenneth W Locke
Kazuko Matsuda
Richard E Gammans
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of BRPI0814624A2 publication Critical patent/BRPI0814624A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0814624-1A2A 2007-07-11 2008-07-08 Tratamento de doença neurodegenerativa progresiva com ibudilaste BRPI0814624A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92974507P 2007-07-11 2007-07-11
US4218108P 2008-04-03 2008-04-03
PCT/US2008/069417 WO2009009529A1 (en) 2007-07-11 2008-07-08 Treatment of progressive neurodegenerative disease with ibudilast

Publications (1)

Publication Number Publication Date
BRPI0814624A2 true BRPI0814624A2 (pt) 2015-01-27

Family

ID=39789775

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814624-1A2A BRPI0814624A2 (pt) 2007-07-11 2008-07-08 Tratamento de doença neurodegenerativa progresiva com ibudilaste

Country Status (14)

Country Link
US (10) US8138201B2 (pt)
EP (2) EP2567699A1 (pt)
JP (2) JP5468001B2 (pt)
CN (1) CN101848712B (pt)
AU (1) AU2008275148A1 (pt)
BR (1) BRPI0814624A2 (pt)
CA (2) CA2693697C (pt)
DK (1) DK2187882T3 (pt)
ES (1) ES2402175T3 (pt)
HR (1) HRP20130057T1 (pt)
PL (1) PL2187882T3 (pt)
PT (1) PT2187882E (pt)
TW (1) TW200918051A (pt)
WO (1) WO2009009529A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011013902A (es) * 2009-06-19 2012-02-23 Teva Pharma Tratamiento de esclerosis multiple con laquinimod.
CA2766632A1 (en) 2009-06-23 2010-12-29 Medicinova, Inc. Enantiomeric compositions of 2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one and related methods
CN102480960A (zh) * 2009-07-30 2012-05-30 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
SI2467372T1 (sl) * 2009-08-10 2016-09-30 Teva Pharmaceutical Industries Ltd. Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
WO2011080733A1 (en) * 2010-01-04 2011-07-07 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
EA201290859A1 (ru) * 2010-03-03 2013-04-30 Тева Фармасьютикал Индастриз Лтд. Лечение люпус-артрита с использованием лаквинимода
BR112012022187A2 (pt) * 2010-03-03 2015-09-22 Teva Pharma tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
AU2012322706A1 (en) 2011-10-12 2014-05-22 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US9161935B2 (en) 2012-02-03 2015-10-20 Teva Pharmaceutical Industries, Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
CN103255142B (zh) * 2012-02-21 2017-07-25 上海转基因研究中心 一种利用RNAi调控内源性朊蛋白表达的方法及其应用
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
CN103505731A (zh) * 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
FR3000746A1 (fr) 2013-01-04 2014-07-11 Centre Nat Rech Scient Peptide pour son utilisation dans le traitement des neuronopathies motrices
HK1218251A1 (zh) * 2013-02-15 2017-02-10 Teva Pharmaceutical Industries Ltd. 用拉喹莫德治療多發性硬化症
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
US20150366847A1 (en) * 2014-06-20 2015-12-24 Medicinova, Inc. Combination of geranylgeranylacetone and ibudilast and methods of using same
CA2961187A1 (en) * 2014-09-16 2016-03-24 Teva Pharmaceuticals Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
EP3223815B1 (en) * 2014-11-26 2021-07-28 MediciNova, Inc. Combination of ibudilast and riluzole and methods of using same
WO2016086000A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. A combination of geranygeranylacetone, ibudilast, and riluzole and methods of using same
CN105395511A (zh) * 2015-12-07 2016-03-16 黑龙江省智诚医药科技有限公司 一种异丁司特缓释微丸及其制备方法
US20190151294A1 (en) * 2016-05-10 2019-05-23 Medicinova, Inc. Treatment of alcoholism and depression and/or dysphoric mood using ibudilast
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
JP2020504721A (ja) 2016-12-22 2020-02-13 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． イブジラストを使用した多形膠芽腫の治療方法
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
EP3740205B1 (en) * 2018-02-12 2023-09-20 MediciNova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients
US10744123B2 (en) 2018-02-12 2020-08-18 Medicinova, Inc. Methods and dosing regimens using ibudilast and a second agent for cancer therapy
US10946071B2 (en) 2018-10-09 2021-03-16 Medicinova, Inc. Combination of ibudilast and interferon-beta and methods of using same
WO2020081941A1 (en) 2018-10-19 2020-04-23 Medicinova, Inc. Methods of treating ophthalmic disease/disorder or injury with ibudilast
AU2019397067A1 (en) 2018-12-12 2021-07-22 Autobahn Therapeutics, Inc. Novel thyromimetics
CN113473993B (zh) * 2019-02-26 2024-06-04 巴伦西亚大学 治疗运动神经元疾病的方法和组合物
EP3931180A1 (en) 2019-03-01 2022-01-05 Autobahn Therapeutics, Inc. Novel thyromimetics
US20220347159A1 (en) * 2019-06-11 2022-11-03 Yale University Novel treatment for wolfram syndrome
US11865214B2 (en) 2019-09-23 2024-01-09 Medicinova, Inc. Ibudilast oral formulations and methods of using same
EP4132521A1 (en) * 2020-04-06 2023-02-15 MediciNova, Inc. Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
WO2022164948A1 (en) 2021-01-29 2022-08-04 Medicinova, Inc. Methods of treating chemical gas exposure
US12005049B2 (en) 2021-07-26 2024-06-11 Medicinova, Inc. Methods of preventing cancer metastasis
CA3231869A1 (en) 2021-09-21 2023-03-30 Medicinova, Inc. Ibudilast in combination therapy for use in the treatment of glioblastoma
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
US12171752B2 (en) 2022-02-01 2024-12-24 Medicinova, Inc. Methods of treating post-COVID condition(s)
US20250179503A1 (en) * 2022-03-28 2025-06-05 Praxis Precision Medicines, Inc. Methods of using oligomeric compounds to treat scn2a-related disorders
US20240016729A1 (en) 2022-07-13 2024-01-18 Medicinova, Inc. Injectable formulations of ibudilast

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009127A1 (fr) * 1998-08-10 2000-02-24 Kyorin Pharmaceutical Co., Ltd. Traitements contre la sclerose en plaques
CA2427430A1 (en) 2000-11-02 2002-06-13 Research Foundation Of City University Of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
DE602004031356D1 (de) 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
BRPI0518829A2 (pt) 2004-12-06 2008-12-09 Avigen Inc mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas
WO2007047978A2 (en) * 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition

Also Published As

Publication number Publication date
CA2970273C (en) 2020-04-14
AU2008275148A1 (en) 2009-01-15
JP2010533193A (ja) 2010-10-21
US20170014390A1 (en) 2017-01-19
US20090062330A1 (en) 2009-03-05
EP2567699A1 (en) 2013-03-13
JP5468001B2 (ja) 2014-04-09
CN101848712B (zh) 2013-07-24
US20150011581A1 (en) 2015-01-08
US20140171463A1 (en) 2014-06-19
CA2693697A1 (en) 2009-01-15
PT2187882E (pt) 2013-04-17
US20250073213A1 (en) 2025-03-06
US20170020851A1 (en) 2017-01-26
CN101848712A (zh) 2010-09-29
ES2402175T3 (es) 2013-04-29
EP2187882A1 (en) 2010-05-26
HRP20130057T1 (hr) 2013-02-28
US11083713B2 (en) 2021-08-10
DK2187882T3 (da) 2013-04-08
US20130217718A1 (en) 2013-08-22
PL2187882T3 (pl) 2013-05-31
US8138201B2 (en) 2012-03-20
TW200918051A (en) 2009-05-01
US9314452B2 (en) 2016-04-19
US8338453B2 (en) 2012-12-25
WO2009009529A1 (en) 2009-01-15
JP2014062118A (ja) 2014-04-10
CA2693697C (en) 2017-07-25
US20220168283A1 (en) 2022-06-02
US9114136B2 (en) 2015-08-25
US11944607B2 (en) 2024-04-02
CA2970273A1 (en) 2009-01-15
US20120214839A1 (en) 2012-08-23
EP2187882B1 (en) 2013-01-09
US20200093805A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
BRPI0814624A2 (pt) Tratamento de doença neurodegenerativa progresiva com ibudilaste
SMT201500186B (it) Autoanticorpi umani anti-alfa-sinucleina
BRPI0917567A2 (pt) tratamento de doença respiratória
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0811265A2 (pt) Tratamento de sinucleinopatias
BRPI0813908A2 (pt) Seringa com mecanismo de desativar
EP2296593A4 (en) MEDICAL HEAD COVER
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
BRPI0916931A2 (pt) agentes terapêuticos
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
ME03508B (me) Kombinovana terapija za liječenje dijabetesa
BRPI0811919A2 (pt) Medicamento para tratamento do mal de alzheimer
DK2173831T3 (da) Brøndbehandling
DK2627345T3 (da) Formuleringer til behandling af sygdomme i de øvre luftveje
BRPI0810559A2 (pt) Macadores de doenças
EP3381471C0 (en) Pain treatment
BRPI0920743A2 (pt) ribonucleases terapeuticas
BRPI1011535A2 (pt) tratamento de distúrbios resistentes à insulina.
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI1010516A2 (pt) Métodos de tratamento de edema relacionados à isquemia-reperfusão
EP2368499A4 (en) TREATMENT INSTRUMENT
BRPI0818598A2 (pt) agentes terapêuticos - 802
EP2146744A4 (en) THERAPEUTIC BETA-GLUCAN COMPOSITIONS
HRP20160577T1 (hr) Liječenje osteoartritisa
BRPI0910931A2 (pt) ciclopentanos substituídos terapêuticos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]